Month: August 2026

HighLife Receives CE Mark Approval for Clarity Valve, the Next-Generation Valve for the HighLife TMVR System

London, UK, Aug. 27, 2026 (GLOBE NEWSWIRE) — Transferra, a UK FCA-authorised electronic money institution, has announced its sponsorship of the John Galt Forum, taking place on 7 October 2026 at the Digital Art House in Riga.

LIMASSOL, Cyprus, Aug. 27, 2026 (GLOBE NEWSWIRE) — Harmovest Capital today announced the continued development of its global financial services platform, bringing together technology, international market access, compliance and professional services within an integrated financial ecosystem. The initiative reflects the company’s focus on supporting clients and professional partners across regional markets while strengthening its capabilities in an increasingly interconnected financial landscape.

Lyon, France and Yongin, Republic of Korea – 27 August 2026 – Osivax, a clinical-stage biopharmaceutical company developing differentiated influenza vaccines designed to generate broad-spectrum immune responses, and GC Biopharma, a leading South Korean biopharmaceutical company with extensive experience in vaccines and plasma-derived products, today announced a long-term collaboration to develop and commercialize a next-generation seasonal influenza vaccine candidate designed to provide broader and more durable protection against a wide range of influenza strains.

Uppsala, Aug. 27, 2026 (GLOBE NEWSWIRE) —

Sebastian Blind Passage Bror Hjorthföreningens teckningsstipendiat 2026 5 september – 4 oktober 2026 Bror Hjorths Hus, Uppsala

EI JULKISTETTAVAKSI TAI LEVITETTÄVÄKSI, KOKONAAN TAI OSITTAIN, SUORAAN TAI VÄLILLISESTI, AUSTRALIASSA, KANADASSA, HONGKONGISSA, JAPANISSA, UUDESSA-SEELANNISSA TAI ETELÄ-AFRIKASSA TAI NÄIHIN MAIHIN TAI MILLÄÄN MUULLA ALUEELLA TAI MILLEKÄÄN MUULLE ALUEELLE, JOSSA OSTOTARJOUS OLISI SOVELTUVAN LAIN VASTAINEN. LISÄTIETOJA ALLA KOHDASSA ”TÄRKEÄÄ TIETOA”.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH THE TENDER OFFER WOULD BE PROHIBITED BY APPLICABLE LAW. FOR FURTHER INFORMATION, PLEASE SEE SECTION ENTITLED “IMPORTANT INFORMATION” BELOW.

Communiqué de presse

London, UK – 27 August 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announces the acquisition of CRS Clinical Research Services Berlin GmbH (“CRS Berlin”).

1 A PDUFA date is the target date by which the U.S. Food and Drug Administration (FDA) aims to complete its review and issue a decision on a New Drug Application (NDA) under the Prescription Drug User Fee Act (PDUFA).

1 La date PDUFA correspond à la date cible à laquelle la Food and Drug Administration (FDA) américaine prévoit d’achever la revue d’une demande d’autorisation de mise sur le marché (NDA) et de rendre sa décision, conformément au Prescription Durg User Fee Act (PDUFA).

Akkodis und EKPO validieren den NM20-Brennstoffzellenstack im Wasserstoff-Lkw und bringen die Technologie in den Praxiseinsatz.

Akkodis and EKPO validate the NM20 fuel cell stack in a hydrogen truck, bringing fuel cell technology into real-world logistics.

MENLO PARK, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) — AccuKnox today announced the launch of AgentZ, a platform for building, running, and governing AI agents across teams and workflows. AgentZ brings the agent, its execution environment, tools, workflows, permissions, and governance into a single platform, so organizations can move agents from experiment to production without assembling and maintaining a stack of disconnected components.

CALGARY, AB, Aug. 26, 2026 (GLOBE NEWSWIRE) — Seegnal Inc. (TSXV: SEGN) (“Seegnal” or the “Company”), a global leader in SaaS clinical decision support solutions, is pleased to announce, further to its news releases dated June 2, 2026 and July 21, 2026, that it has closed the first tranche (“Tranche 1”) of its previously announced non-brokered private placement of units in the capital of the Company (each, a “Unit”). The Company is also pleased to announce that it has upsized the private placement to up to CDN$1,850,000 and is expected to close the second tranche by September 30, 2026.

– NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES –

– NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES –

World of Hurt and Otis College Partner to Reimagine First Aid Through Gen Z Creativity

St. Petersburg, Fla., Aug. 26, 2026 (GLOBE NEWSWIRE) — On August 26, 2026, the Raymond James Financial, Inc. (NYSE: RJF) Board of Directors declared a quarterly cash dividend on shares of its common stock of $0.54 per share, payable October 15, 2026 to shareholders of record on October 1, 2026.

AUDUBON, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) — Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the acquisition of Higgs Boson Health, a digital healthcare experience company based in Durham, NC and incubated out of Duke University. With a mission to transform healthcare experience through digital innovation, Higgs Boson will position Globus Medical to shape patient and provider experience throughout the full episode of care.

Global Biorisk Management Service Market demand is rising as organizations across Agriculture, Biotechnology, Healthcare, and Pharmaceuticals formalize biosafety governance through consulting, laboratory, monitoring, and risk assessment services. Tightening regulatory documentation requirements, operational incident learning, and technology-enabled assessment accuracy are converging to drive sustained Biorisk Management Service Market growth through 2033. North America currently leads global adoption with approximately 41% market share, supported by stringent regulations and advanced laboratory density. Verified Market Research® projects the Biorisk Management Service Market will expand from USD 2.06 Billion in 2025 to USD 4.91 Billion by 2033, reflecting a Biorisk Management Service Market Forecast CAGR of 11.4%.

Global Biorisk Management Service Market demand is rising as organizations across Agriculture, Biotechnology, Healthcare, and Pharmaceuticals formalize biosafety governance through consulting, laboratory, monitoring, and risk assessment services. Tightening regulatory documentation requirements, operational incident learning, and technology-enabled assessment accuracy are converging to drive sustained Biorisk Management Service Market growth through 2033. North America currently leads global adoption with approximately 41% market share, supported by stringent regulations and advanced laboratory density. Verified Market Research® projects the Biorisk Management Service Market will expand from USD 2.06 Billion in 2025 to USD 4.91 Billion by 2033, reflecting a Biorisk Management Service Market Forecast CAGR of 11.4%.